Edward Mathers
SlowingNamed in filings at NEAOn the current fund
- Board seats filed
- 25
all filings on record
Named in filings at NEAOn the current fund
all filings on record
last 24 months
from a verified or cited source
| Senti Biosciences Holdings | Biotech & pharma | December 2024 | None on file |
| Cardurion Pharmaceuticals | Biotech & pharma | July 2024 | Bain Capital Life Sciences, Polaris Partners |
| Brenig Therapeutics | Biotech & pharma | July 2024 | None on file |
| MBX Biosciences | Biotech & pharma | November 2022 | Caduceus Capital, Orbimed Asia Partners, Orbimed Genesis |
| Sorriso Pharmaceuticals | Biotech & pharma | December 2021 | None on file |
| Code Biotherapeutics | Biotech & pharma | March 2021 | None on file |
| Affinia Therapeutics | Biotech & pharma | March 2020 | Atlas Venture |
| Curzion Pharmaceuticals | Biotech & pharma | March 2019 | Rivervest |
| Mirum Pharmaceuticals | Biotech & pharma | November 2018 | Rivervest |
| SENTI BIOSCIENCES | Biotech & pharma | February 2018 | None on file |
| Liquidia Technologies | Biotech & pharma | February 2018 | None on file |
| Reneo Pharmaceuticals | Biotech & pharma | December 2017 | Rivervest |
| Akouos | Biotech & pharma | October 2017 | None on file |
| Trevi Therapeutics | Biotech & pharma | July 2017 | None on file |
| Inozyme Pharma | Biotech & pharma | January 2017 | Sofinnova Venture Partners |
| Synlogic | Biotech & pharma | February 2016 | None on file |
| Envisia Therapeutics | Biotech & pharma | October 2015 | None on file |
| Amplyx Pharmaceuticals | Biotech & pharma | October 2015 | Rivervest, Sofinnova Venture Partners |
| RHYTHM METABOLIC | Biotech & pharma | August 2015 | MPM BioVentures, Third Rock Ventures |
| Ra Pharmaceuticals | Biotech & pharma | July 2015 | Pivotal bioVenture Partners |
| SYNLOGIC | Biotech & pharma | March 2015 | Sofinnova Venture Partners |
| SYNLOGIC | Biotech & pharma | July 2014 | Sofinnova Venture Partners |
| Lumena Pharmaceuticals | Biotech & pharma | March 2014 | Rivervest |
| Lumos Pharma | Biotech & pharma | January 2014 | None on file |
| SATORI PHARMACEUTICALS | Biotech & pharma | February 2012 | None on file |
The company and date are what the SEC filing shows, not a statement of investment thesis. A partner can sit on a board for reasons that say nothing about what their firm funds today. The sector is not a filing value: it is Lev’s own classification of each company, shown only when we found a specific, checkable source for it; otherwise it reads “Not yet classified.” “Also on the board from” names another tracked firm with a partner on the same board, both with a clean identity match. It is not a claim either firm led or co-led the round, and “None on file” means no other tracked firm’s partner shares this specific board seat, not that no one else invested. Sorted newest first by default; click a column to change it. Something wrong? Tell us.
Classified sectors of companies where filings name Edward Mathers on the board, based on 25 filed seats with a verified or cited source.